Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 7/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17054383 | 0.94 | HDAC6 (0.57) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL250247 | 0.87 | HDAC6 (0.80) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL31730035 | 0.81 | ALDH1A1 (0.50) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL20234154 | 0.81 | HDAC8 (0.64) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL14115137 | 0.80 | HDAC6 (0.70) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL16198923 | 0.80 | HDAC6 (0.70) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL20306732 | 0.80 | PLAU (0.62) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL23933223 | 0.78 | HDAC8 (0.67) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL19631295 | 0.78 | HDAC6 (1.00) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL21694316 | 0.78 | HDAC6 (0.60) | HDAC8HDAC6HDAC2CA2TPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745129-A2 | COMPOUND HAVING CYCLIC STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-3682881-B1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO CO LTD (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-120004754-A | Preparation method of high-purity N-methyl halogenated benzamide | 福州大学 | 2025-05-16 | — | — | CN | disclosed |
| US-12297187-B2 | Compound having cyclic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| CN-119320379-A | Indazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-113874367-B | Indazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2024009283-A1 | AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-111094255-B | Compounds having cyclic structures | 第一三共株式会社 | 2023-10-03 | — | — | CN | disclosed |
| CN-1326838-C | Benzo[d]azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LTD (GB) | 2007-07-18 | — | — | CN | disclosed |
| EP-1734942-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| CN-1726042-A | Benzo[d]azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LTD (GB) | 2006-01-25 | — | — | CN | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | HDAC8 273/4885HDAC6 1068/4885HDAC2 504/4885 |
| US-12297187-B2 | Compound having cyclic structure | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | HDAC8 712/4885HDAC6 956/4885HDAC2 286/4885 |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | CYP19A1, HSD17B11, CYP51A1 | HDAC8 814/4885HDAC6 2767/4885HDAC2 917/4885 |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | HDAC8 1065/4885HDAC6 1015/4885HDAC2 779/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | HDAC8 2171/4885HDAC6 2962/4885HDAC2 2848/4885 |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | HDAC8 712/4885HDAC6 956/4885HDAC2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.